BioCryst Pharmaceuticals (BCRX) Financial Statements & Analysis

BioCryst Pharmaceuticals (BCRX) Income Statement

BioCryst Pharmaceuticals reported revenue of $874.84M in fiscal 2025 (fiscal year ended Dec 31, 2025), up 94.1% from $450.71M a year earlier. Net income was $263.86M, a net margin of 30.2%. Gross margin was 97.8% and operating margin 39.0%. In the most recent quarter, Q2 fiscal 2026 (ended Jun 30, 2026), revenue was $218.25M, up 33.6% from the same quarter a year earlier.

BioCryst Pharmaceuticals Income Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

BioCryst Pharmaceuticals, Inc. income statement - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
Revenue & Gross Profit
Revenue	874.84	450.71	331.41	270.83	157.17	17.81	48.84	20.65	25.19
Cost of Revenue	183.16	12.49	4.66	259.89	7.26	124.64	4.10	0.47	1.70
Gross Profit	855.76	438.23	326.75	264.42	149.91	-106.83	44.73	20.18	23.48
Operating Expenses
Research & Development	166.13	174.64	216.57	253.30	208.81	122.96	107.07	84.89	66.96
Selling, General & Administrative	344.37	266.13	213.89	159.37	118.82	62.90	37.12	29.51	13.93
Operating Expenses	514.77	440.77	430.46	412.85	327.63	62.90	144.19	114.40	80.90
Operating Income	340.99	-2.54	-103.71	-148.44	-177.72	-169.73	-99.46	-94.22	-57.41
Other Income/Expense
Interest Income	10.67	14.75	15.78	5.13	0.06	0.53	1.93	2.25	1.02
Interest Expense	78.87	98.52	108.24	-99.09	59.29	-14.50	11.89	9.18	8.57
Other Income/Expense	-73.60	-84.41	-122.52	-95.95	-4.09	-8.06	-9.44	-7.03	-8.37
Income
Income Before Tax	267.39	-86.95	-226.23	-244.38	-181.81	-182.81	-108.90	-101.25	-65.78
Income Tax Expense	3.53	1.93	0.31	2.73	2.25	0.00	0.00	0.00	0.00
Net Income	263.86	-88.88	-226.54	-247.12	-184.06	-182.81	-108.90	-101.25	-65.78
Net Income - Continuous Operations	263.86	-88.88	-226.54	-247.12	-184.06	-182.81	-108.90	-101.25	-65.78
Net Income - Discontinued Operations	-	-	-	-	-	-	-	-	-
EBITDA	350.79	12.81	-116.34	-146.18	-121.74	-168.98	-96.28	-90.37	-56.51
EBIT	347.30	-1.28	-117.99	-148.44	-177.72	-169.73	-	-	-
Depreciation & Amortization	1.39	1.25	1.66	2.25	0.78	0.75	0.72	0.77	0.70
Earnings Per Share
Basic EPS	1.00	-	-1.00	-1.00	-1.00	-1.00	-1.00	-1.00	-1.00
Diluted EPS	1.00	-	-1.00	-1.00	-1.00	-1.00	-1.00	-1.00	-1.00
Basic Shares Outstanding	209.89	206.70	192.20	185.91	179.12	167.27	115.60	103.19	84.45
Diluted Shares Outstanding	218.58	206.70	192.20	185.91	179.12	167.27	115.60	103.19	84.45

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About BioCryst Pharmaceuticals Financial Statements

What was BioCryst Pharmaceuticals's revenue in fiscal 2025?

BioCryst Pharmaceuticals reported revenue of $874.84M in fiscal 2025 (fiscal year ended Dec 31, 2025). That was up 94.1% from $450.71M a year earlier.

Is BioCryst Pharmaceuticals profitable?

Yes. BioCryst Pharmaceuticals earned net income of $263.86M in fiscal 2025, a net margin of 30.2%. In fiscal 2024 it lost $88.88M.

What is BioCryst Pharmaceuticals's operating margin?

BioCryst Pharmaceuticals's operating income was $340.99M on revenue of $874.84M in fiscal 2025, an operating margin of 39.0%, compared with -0.6% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition